Transforming growth factor-β1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects
- 1 January 2002
- journal article
- Published by Springer Nature in Leukemia
- Vol. 16 (1) , 94-105
- https://doi.org/10.1038/sj.leu.2402334
Abstract
A number of cytokines modulate self-renewal and differentiation of hematopoietic elements. Among these is transforming growth factor beta1 (TGF-beta1), which regulates cell cycle and differentiation of hematopoietic cells, but has pleiotropic activities depending on the state of responsiveness of the target cells. It has been previously shown by us and other authors that TGF-beta1 maintains human CD34(+) hematopoietic progenitors in an undifferentiated state, independently of any cell cycle effects, and that depletion of TGF-beta1 triggers differentiation accompanied by a decrease in CD34 antigen expression. In the present work, we show that exogenous TGF-beta1 upregulates the human CD34 antigen in the CD34(+) cell lines TF-1 and KG-1a, but not in the more differentiated CD34(-) cell lines HL-60 and K-562. We further studied this effect in the pluripotent erythroleukemia cell line TF-1. Here, TGF-beta1 did not effect cell growth, but induced transcriptional activation of full-length CD34 and prevented differentiation induced by differentiating agents. This effect was associated with nuclear translocation of Smad-2, activation of TAK-1, and with a dramatic decrease in p38 phosphorylation. In other systems TGF-beta1 has been shown to activate a TGF-beta-activated kinase 1 (TAK1), which in turn, activates p38. The specific inhibitor of p38 phosphorylation, SB202190, also increased CD34 RNA expression, indicating the existence of a link between p-38 inhibition by TGF-beta1 and CD34 overexpression. Our data demonstrate that TGF-beta1 transcriptionally activates CD34 and prevents differentiation of TF-1 cells by acting independently through the Smad, TAK1 and p38 pathways, and thus provide important clues for the understanding of hematopoietic development and a potential tool to modify response of hematopoietic cells to mitogens or differentiating agents.Keywords
This publication has 47 references indexed in Scilit:
- Role of mitogen-activated protein kinases as downstream effectors of transforming growth factor-β in mesangial cellsKidney International, 2000
- Technical Aspects and Clinical Impact of Hematopoietic Progenitor Subset QuantificationThe International Journal of Cell Cloning, 2000
- TGF-β1 Stimulation of Fibronectin Transcription in Cultured Human Lung Fibroblasts Requires Active Geranylgeranyl Transferase I, Phosphatidylcholine-Specific Phospholipase C, Protein Kinase C-δ, and p38, But Not erk1/erk2Archives of Biochemistry and Biophysics, 2000
- GM-CSF RESCUES TF-1 CELLS FROM GROWTH FACTOR WITHDRAWAL-INDUCED, BUT NOT DIFFERENTIATION-INDUCED APOPTOSIS: THE ROLE OF BCL-2 AND MCL-1Cytokine, 1999
- Involvement of the p38 Mitogen-activated Protein Kinase Pathway in Transforming Growth Factor-β-induced Gene ExpressionPublished by Elsevier ,1999
- Transforming growth factor β inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma protein phosphorylation at serine 795Experimental Hematology, 1999
- Purification and Identification of a Major Activator for p38 from Osmotically Shocked CellsJournal of Biological Chemistry, 1996
- Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb.The Journal of Experimental Medicine, 1994
- The Transforming Growth Factor-beta FamilyAnnual Review of Cell Biology, 1990
- Latent form of transforming growth factor-β1 acts as a potent growth inhibitor on a human erythroleukemia cell lineBiochemical and Biophysical Research Communications, 1990